SAN ANTONIOTamoxifen (Nolvadex) therapy not only prevents breast cancer but also benign breast disease in high-risk women, according to a study by the National Surgical Adjuvant Breast and Bowel Project (NSABP) presented at the 24th San Antonio Breast Cancer Symposium (abstract 7). Elizabeth Tan-Chiu, MD, of the NSABP, reported the findings.
In 1998, she said, the NSABP P-I trial established that tamoxifen(Drug information on tamoxifen) reduces the incidence of invasive breast cancer (NSABP B-14), as well as ductal carcinoma in situ and lobular carcinoma in situ (NSABP B-24) by about 50% in women at high risk for breast cancer.
"These findings have been described as an early treatment of subclinical invasive breast cancers rather than a true preventive effect," Dr. Tan-Chiu said. "It was pertinent, therefore, to look at the effect of tamoxifen on the non-premalignant (benign) lesions of the breast." She noted that estrogen receptors are expressed on benign as well as malignant breast lesions.
The patient population included 13,388 women determined to be at high risk for developing breast cancer by the Gail model. Pathology reports on all breast biopsies performed during the study were collected prospectively. For each histologic diagnosis, the relative risk between tamoxifen- and placebo-treated women was evaluated. The median follow-up was 54.6 months.
Tamoxifen therapy reduced the overall incidence of benign breast disease by 28% (P < .001), the total number of women undergoing biopsies by 12%, and the total number of biopsies by 22% (P < .001), Dr. Tan-Chiu reported.In the NSABP P-1 trial, about 2,200 biopsies were performed. In tamoxifen recipients, there were about 400 fewer total biopsies, and about 150 fewer women undergoing biopsies. The effect of tamoxifen on biopsies was most evident among women undergoing two or more biopsies vs only one, and for premenopausal women, in whom the number of biopsies was reduced by 35%, she said.
Most, but not all, histologic types of benign lesions were affected by tamoxifen therapy). Statistically significant relative risk reductions (P < .001 for most) were seen in the categories of adenosis (41%), cysts (32%), duct ectasia (29%), fibrocystic disease (33%), hyperplasia (39%), and metaplasia (49%). Tamoxifen reduced the risk of typical hyperplasia by 40% and atypical hyperplasia by 32%.